Skip to main
ACON
ACON logo

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion Inc is experiencing significant commercial momentum, evidenced by new agreements with major healthcare providers such as the Spine Institute of Louisiana, Medical Imaging Center of Southern California, and affiliates of RadNet, indicating a broadening market presence. The company reported a remarkable 132% year-over-year growth in scans for the second quarter, coupled with a 76% year-over-year increase in revenues, which reinforces the potential for continued growth as Nociscan adoption accelerates. These factors suggest a strengthening business model and increasing demand for its proprietary services, positioning Aclarion favorably within the healthcare technology sector.

Bears say

Aclarion Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to slower-than-expected traction with payers, which may hinder revenue growth from its Nociscan product. The company is adjusting its fiscal year 2025 earnings per share estimate downward to $(15.08), reflecting an anticipated increase in marketing and administrative expenses that could further strain profitability. Additionally, various risks, including balance sheet and liquidity issues, regulatory hurdles, and competitiveness in the healthcare market, present ongoing threats to the company's financial stability and long-term viability.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.